Eupraxia Pharmaceuticals (EPRX) vs Puma Biotechnology (PBYI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Puma Biotechnology (PBYI) has outperformed Eupraxia Pharmaceuticals (EPRX) over the past year, gaining 90.6% versus a gain of 23.3%. Puma Biotechnology is the larger company by market cap ($531.2 million vs $492.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EPRX | PBYI |
|---|---|---|
| Share price | $7.46 | $10.29 |
| Market cap | $492.91M | $531.17M |
| 1-day change | -1.45% | +3.21% |
| YTD return | +0.26% | +67.56% |
| 1-year return | +23.29% | +90.63% |
| 5-year return | — | +64.79% |
| P/E ratio (TTM) | — | 20.18 |
| Forward P/E | — | 29.40 |
| EPS (TTM) | $-1.02 | $0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.32 | $10.35 |
| 52-week low | $5.25 | $4.58 |
| Distance from 52-week high | -19.96% | -0.58% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +119.17% | — |
| Average volume | 575.10K | 320.69K |
| Shares outstanding | 66.07M | 51.62M |
| Employees | 49 | 179 |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBYI has outperformed EPRX by 67.3 percentage points over the past year.
About Eupraxia Pharmaceuticals
EPRX stock →Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Health Care · Pharmaceuticals and Biotechnology · 49 employees
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
EPRX vs PBYI FAQ
Which is bigger, Eupraxia Pharmaceuticals or Puma Biotechnology?
Puma Biotechnology (PBYI) is larger, with a market capitalization of $531.17M compared with $492.91M for Eupraxia Pharmaceuticals (EPRX).
Which stock has performed better over the past year, EPRX or PBYI?
PBYI returned +90.63% over the past 12 months, compared with +23.29% for EPRX (price return, excluding dividends). Past performance does not predict future results.
Are Eupraxia Pharmaceuticals and Puma Biotechnology in the same industry?
Both are in the Health Care sector, but in different industries: Pharmaceuticals and Biotechnology for Eupraxia Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Puma Biotechnology.